University of Illinois at Chicago
Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP is an Assistant Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago College of Pharmacy. He completed a 3-year Infectious Diseases Pharmacotherapy Fellowship at the University of Illinois at Chicago in June 2017. He graduated from Ohio Northern University Raabe College of Pharmacy in 2012 and completed his Postgraduate Year 1 training in 2013 and Postgraduate Year 2 in Infectious Diseases in 2014 at The Ohio State University Wexner Medical Center in Columbus, Ohio. Dr. Wenzler’s research is centered around the pharmacokinetics and pharmacodynamics of antimicrobials in both the in vitro and clinical arenas as well as outcomes-based research related to infectious diseases. His laboratory research focuses on discovering optimal antimicrobial treatment regimens against multidrug resistant bacteria, including evaluating synergistic antimicrobial combinations targeted at emerging super resistant Gram negative pathogens such as those harboring metallo-beta-lactamase and class D serine beta-lactamase enzymes. He is also interested in the activity of antimicrobials in the genitourinary tract and optimizing the use of inhaled antibiotics for the treatment of pneumonia. His primary clinical research emphasis is investigating antimicrobial pharmacokinetics after novel dosing regimens in healthy volunteers and in special patient populations including critically ill patients and those receiving forms of hemodialysis. His outcomes research attempts to translate and apply the in vitro and clinical research findings to patients afflicted with infectious diseases syndromes, specifically exploring the impact of bacterial genotypic-phenotypic relationships on the clinical outcomes of patients infected with resistant pathogens.
Disclosure: Allergan Plc (Individual(s) Involved: Self): Speakers' bureau; Astellas Pharma (Individual(s) Involved: Self): Speakers' bureau; GenMark Diagnostics (Individual(s) Involved: Self): Consultant; Melinta Therapeutics (Individual(s) Involved: Self): Speakers' bureau; Shionogi Inc (Individual(s) Involved: Self): Consultant
Saturday, October 24, 2020
1:15pm – 3:00pm EDT